Developing a new treatment for preeclampsia
Official title: Advancing a novel therapy for preeclampsia
Funded at Larix Bioscience, LLC · NIH-10478384 · Data updated 2026-11-12
This study is looking at a new way to help women with severe preeclampsia by testing a medication called Digibind to see if it can improve their health during pregnancy.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Larix Bioscience, LLC NIH-funded |
| Lab location | 1 site (Sunnyvale, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $385,000 |
| NIH project number | 1R43HD107719-01A1 |
| Project ID | NIH-10478384 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant women diagnosed with severe preeclampsia.
✕Less likely to help
Patients who are not pregnant or those with mild preeclampsia may not benefit from this research.
What this research studies
This research focuses on creating a novel therapy for preeclampsia, a serious pregnancy complication characterized by high blood pressure and protein in the urine. The approach involves investigating the role of an endogenous substance known as marinobufagenin, which is believed to contribute to the condition. The study aims to evaluate the effectiveness of Digibind, an existing medication, in improving outcomes for patients with severe preeclampsia. By targeting the underlying mechanisms of the disease, the research hopes to provide a more effective treatment option for affected women.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly improves the health outcomes for pregnant women suffering from preeclampsia.
How similar studies have gone: Previous clinical trials have shown promising results using similar approaches, indicating potential for success in this area.
Where this research is happening
-
Larix Bioscience, LLC
Sunnyvale, United States Active
Researchers
- Principal investigator: Yu, Bo — Larix Bioscience, LLC
- Study coordinator: Yu, Bo
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
-
Folate Receptor Beta and its Role in Preeclampsia
This study explores how a protein called folate receptor beta on placental immune cells may drive or worsen preeclampsia in pregnancy, with hopes of finding new ways to prevent or treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.